DESCRIBE THE PROCESS BY WHICH YOUR DRUG WILL BE EVALUATED AS A SUITABLE AND SAFE THERAPY FOR THE DISEASE.
DESCRIBE THE PROCESS BY WHICH YOUR DRUG WILL BE EVALUATED AS A SUITABLE AND SAFE THERAPY FOR THE DISEASE.
Drugs Name Venlafaxine Drugs Class SNRI Drug indication depression 250 words Development of your drug (The development team) In this section, you should describe the process by which your drug will be evaluated as a suitable and safe therapy for the disease. This should include what will be needed for pre-clinical and clinical testing and for registration to enable it to go on sale. Assignment 3 written submission 450 words count. Marking guide The submission should contain a title name, and which part of the presentation you undertook – market researcher, The marking guide for this submission is as follows. 1. Section 1: A brief summary (no more than 100 words) outlining the overall group presentation. This should describe the drug that was researched and the conclusions reached by your group, and are designed to place your contribution in context. This is worth 4 marks. 2. Section 2: A detailed account of your contribution to the presentation. It should describe the important points of your individual research and illustrate the significance of your findings within the assignment. This section will comprise the bulk of submission (400 words) and is worth 12 marks. 3. Style and formatting: The summary should be clearly written and presented in a professional style appropriate for a business document. This is worth 4 marks. Just as your presentation was delivered as a presentation to the board of a drug company, this submission should be considered as a written submission to the same board, and therefore be presented using clear, professional language.
Instruction:
Drugs Name Venlafaxine
Drugs Class SNRI
Drug indication depression
250 words
Development of your drug (The development team)
In this section, you should describe the process by which your drug will be evaluated as a suitable and safe therapy for the disease. This should include what will be needed for pre-clinical and clinical testing and for registration to enable it to go on sale.
Assignment 3 written submission 450 words count.
Marking guide
The submission should contain a title name, and which part of the presentation you undertook – market researcher,
The marking guide for this submission is as follows.
1. Section 1: A brief summary (no more than 100 words) outlining the overall group presentation. This should describe the drug that was researched and the conclusions reached by your group, and are designed to place your contribution in context. This is worth 4 marks.
2. Section 2: A detailed account of your contribution to the presentation. It should describe the important points of your individual research and illustrate the significance of your findings within the assignment. This section will comprise the bulk of submission (400 words) and is worth 12 marks.
3. Style and formatting: The summary should be clearly written and presented in a professional style appropriate for a business document. This is worth 4 marks.
Just as your presentation was delivered as a presentation to the board of a drug company, this submission should be considered as a written submission to the same board
. .
The post DESCRIBE THE PROCESS BY WHICH YOUR DRUG WILL BE EVALUATED AS A SUITABLE AND SAFE THERAPY FOR THE DISEASE. appeared first on My Nursing Writer.
